FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBGlaxoSmithKline announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory ...
FDA granted accelerated approval to belantamab mafodotin-blmf …
WEBOn August 5, 2020, the Food and Drug Administration granted accelerated approval to belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) for adult patients with relapsed or refractory...
GSK builds case for Blenrep's return in myeloma, showdown with …
WEBJun 2, 2024 · If approved, Blenrep, a BCMA-directed ADC, will compete with J&J and Legend Biotech’s powerful BCMA CAR-T therapy, Carvykti, in second-line treatment, plus BMS' rival CAR-T, Abecma, in later...
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or ...
GSK details Blenrep combo data that could bring the multiple …
WEBFeb 5, 2024 · GSK telegraphed the latest phase 3 win in a surprise announcement in November, a year after the company pulled Blenrep as a monotherapy for heavily pretreated multiple myeloma patients in the...
FDA approves GSK's Blenrep for advanced multiple myeloma
WEBSep 15, 2024 · Blenrep (belantamab mafodotin) has been approved in patients who have received at least four therapies including an anti-CD38 such as Darzalex, a proteasome inhibitor and an immunomodulatory...
Blenrep combination reduced the risk of disease progression or …
WEBJun 2, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory ...
FDA Approves Blenrep for Heavily Pretreated Multiple Myeloma …
WEBAug 7, 2020 · The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment for heavily pretreated adults with relapsed or refractory multiple myeloma, its developer, GlaxoSmithKline, announced.
Phase III Blenrep Trial | Int'l Myeloma Foundation
WEBNov 27, 2023 · GSK Announces Positive Results in a Phase III Trial of Blenrep. On November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma.
GlaxoSmithKline jumps into myeloma with 'homemade' anti-BCMA drug Blenrep
WEBAug 6, 2020 · The FDA late Wednesday green-lighted Blenrep—formerly known as belantamab mafodotin—a first-in-class antibody-drug conjugate for multiple myeloma patients who have already tried four other...
Skip to content